Global Toll Like Receptor 8 (CD288 or TLR8) Pipeline Review 2016: Therapeutics Report Covering 9 Companies & 8 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016" report to their offering.

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 16 molecules. Out of which approximately 16 molecules are developed by Companies. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 5 and 4 respectively.

Toll Like Receptor 8 (CD288 or TLR8) Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

Toll Like Receptor 8 - Pipeline Review, H2 2016, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Toll Like Receptor 8 Overview
  3. Therapeutics Development
  4. Pipeline Products for Toll Like Receptor 8 - Overview
  5. Pipeline Products for Toll Like Receptor 8 - Comparative Analysis
  6. Toll Like Receptor 8 - Therapeutics under Development by Companies
  7. Toll Like Receptor 8 - Therapeutics under Investigation by Universities/Institutes
  8. Toll Like Receptor 8 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Toll Like Receptor 8 - Products under Development by Companies
  13. Toll Like Receptor 8 - Products under Investigation by Universities/Institutes
  14. Toll Like Receptor 8 - Companies Involved in Therapeutics Development
  • 3M Drug Delivery Systems
  • Foamix Pharmaceuticals Ltd.
  • Folia Biotech Inc.
  • Galderma S.A.
  • Idera Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Resolve Therapeutics, LLC
  • VentiRx Pharmaceuticals, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/vt8rp6/toll_like

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs